Short answer
Exelixis Inc (EXEL) filed its Q3 2018 10-Q quarterly report on Nov 1, 2018 for the quarter ended Sep 28, 2018.
Exelixis Inc Q3 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $225.4M, up from $152.5M YoY, with product revenue $162.9M vs $96.4M
- CABOMETYX best performer: $158.3M vs $90.4M; COMETRIQ weakest, $4.7M vs $6.1M
- Net income $126.6M vs $81.4M; gross margin percentages not disclosed
- Cash and investments $750.3M vs $457.2M at December 31, 2017; nine-month operating cash flow $311.1M vs $112.3M
- Near-term headwinds: competition, generic risk, reimbursement pressure, drug-price controls, rising R&D expenses
Risk Factors
- Newly added healthcare compliance risk: June 2018 CCPA expands California privacy rights, with penalties and private data-breach actions effective January 1, 2020
- Most materially updated regulatory risk: February 2018 FDA cabozantinib bioequivalence guidance may signal generic ANDA development
- Commercial risk: IMblaze370 failed its primary endpoint in May 2018, weakening COTELLIC expansion prospects
- Operational risk: Second-quarter 2018 headquarters relocation from South San Francisco to Alameda may drive employee turnover
- Financial risk: Cash and investments increased to $750.3 million at September 30, 2018, including $748.7 million available for operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Exelixis Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.